For example, phase IIa clinical trials for the RTS,S pre-erythrocytic malaria vaccine candidate showed a correlation between prolonged CD4+ and CD8+ T cell IFN-γ responses against a malaria-specific protein and protection upon challenge infection in human volunteers [30]. Here, CD8A is linked to malaria.